Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Circassia Pharmaceuticals ( (GB:NIOX) ).
NIOX Group Plc has received a revised proposal from Keensight Capital for a potential cash offer to acquire the company at 81 pence per share, following a previous offer of 78 pence per share. The board is considering the proposal, which is subject to due diligence, and has also initiated a private sale process to explore other potential offers, though no firm offers have been made yet.
More about Circassia Pharmaceuticals
NIOX Group Plc is a medical device company specializing in point-of-care asthma diagnosis, monitoring, and management solutions.
YTD Price Performance: -3.49%
Average Trading Volume: 641,108
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £244.8M
For a thorough assessment of NIOX stock, go to TipRanks’ Stock Analysis page.